Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...
WIB_icon

Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL

Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...
WIB_icon

Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?

A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...
WIB_icon

Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma

Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...
WIB_icon

Ibrutinib and Palbociclib: A New Combination for Mantle Cell Lymphoma?

The combination of ibrutinib and the CDK-4/6 inhibitor palbociclib could be safely administered to patients with previously treated mantle cell lymphoma (MCL), according to...
WIB_icon

A Pediatric Regimen Is Effective for Adolescents and Young Adults With ALL

Adolescents and young adults (AYAs) with newly diagnosed acute lymphocytic leukemia (ALL) who received a pediatric-inspired regimen had better survival outcomes than historical controls,...
WIB_icon

Study Identifies Genetic Markers That Predict Radiation-Induced Breast Cancer After Hodgkin Lymphoma

The risk of developing breast cancer is high in women with Hodgkin lymphoma (HL) who have undergone chest radiotherapy (RT), but the role of...
WIB_icon

Azacitidine Maintenance Improves Disease-Free Survival in Older Patients with Newly Diagnosed AML

Older patients with acute myeloid leukemia (AML) in complete remission (CR) who received maintenance therapy with subcutaneous azacitidine had longer disease-free survival (DFS), compared...
WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...
Advertisement

Current Issue

May 2019, Volume 5, Issue 6

This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.